Some links on our site may earn us a commission at no extra cost to you. Learn more.
This article is for general informational purposes only and is not medical advice. TENS devices are not appropriate for everyone. People with pacemakers or other implanted electronic devices, pregnant women, and people with certain heart conditions should talk to a doctor before using one. Talk to a healthcare provider about any chronic pain condition rather than relying on a TENS device alone.
Published August 10, 2026. Prices and specs checked September 1, 2026.
Wearable TENS pain relief now comes with an ownership question. All three devices here are real, but two changed hands or channels since the last check. Only iReliev sells the way it always has. Quell 2.0’s maker, NeuroMetrix, was acquired by electroCore in 2025, and electroCore’s newer “Quell Fibromyalgia” product is prescription-only. That is a different regulatory category from the original OTC device. Omron’s Avail PM601 ($199.99 where still listed) is missing from Omron’s own current TENS lineup, which shows only the single-channel, wired PM500 ($79.99) and the PM400. iReliev ($219.95 on ireliev.com, list $249.95) is the one device selling under the same name, from the same maker, the same way as before.
I have shopped for recovery gear for years, after long days on whitewater rafts, on boats around the Keys and through farm summers. Heating wraps, braces and massage tools all taught me the same thing. The spec sheet rarely says who will answer the phone in a year, or what the refills cost. So I check the maker first, then the consumables, then the price.
Which wearable TENS pain relief device scores best?
iReliev, by a wide margin. Price alone will not tell you which of these is still the product you think it is. So the tally below uses four weighted axes.
| Axis (weight) | Quell 2.0 | Omron Avail PM601 | iReliev |
|---|---|---|---|
| Maker continuity (30): is the seller the company that built it? | 10 / 30: NeuroMetrix was acquired by electroCore in 2025, and the OTC and prescription lines have split. | 15 / 30: Omron is stable, but this model is absent from its current TENS catalog. | 28 / 30: same maker, same product, no ownership or channel change found. |
| Claims and regulatory history (25): checked against FTC and FDA records | 10 / 25: the $4 million 2020 FTC settlement over broad pain-relief claims is confirmed on ftc.gov. The 510(k) clearance was never revoked. | 22 / 25: no FTC action found, and FDA clearance is stated on the maker’s own materials. | 20 / 25: FDA clearance is claimed on listings and found in the FDA’s GUDID registry. We could not match it to a specific 510(k) number. |
| Current availability from the maker (25): buyable today from the company that makes it | 15 / 25: third-party retailers still list it, but the maker’s direct path is unclear after the acquisition. | 8 / 25: not on Omron’s current pain-management page, and found only through third-party retailers. | 25 / 25: listed and purchasable directly on ireliev.com today. |
| Price (20): cheaper scores higher | 8 / 20: $300-$350, the most expensive by a wide margin. | 20 / 20: $199.99 where listed, the lowest of the three. | 16 / 20: $219.95 on ireliev.com (list $249.95). |
| Total | 43 | 65 | 89 |
Why does iReliev win the tally?
iReliev earns the win on the axis that matters most here. It is the one product still sold, unchanged, by the company that built it. Omron’s hardware reputation carries it to second despite Avail’s disappearance from the current lineup. Quell scores lowest, but not because the device stopped working. Who is selling it, and under what regulatory status, is now an open question.
Who owns Quell 2.0 now?
electroCore, which completed its acquisition of NeuroMetrix in May 2025. Quell 2.0 still costs $300 for the standard kit or $350 with Sport strips, worn on the upper calf. It is still FDA-cleared through the 510(k) pathway as a Class II device. What changed is the company. NeuroMetrix now operates as electroCore’s subsidiary. electroCore’s own executives have talked publicly about leaning on VA hospital distribution channels rather than a purely direct-to-consumer model going forward.
Is Quell Fibromyalgia the same as Quell 2.0?
No. electroCore has pushed a distinct product, “Quell Fibromyalgia.” Its own marketing describes it as “the first and only FDA-authorized wearable device that helps to reduce symptoms of fibromyalgia in adults with high pain sensitivity.” It was authorized under the FDA’s De Novo pathway in May 2022 and is sold by prescription only. That is a different regulatory category from the original OTC Quell 2.0.
Some current third-party listings for Quell 2.0 itself say “prescription only.” That does not match its original OTC clearance. We could not resolve the discrepancy from quellrelief.com’s own store, which now redirects to a support portal for existing users rather than a public storefront.
Does the 2020 FTC settlement still matter?
Yes, as context. NeuroMetrix paid $4 million for claiming Quell released “natural pain blockers” throughout the body. The FTC said it also claimed to treat conditions like fibromyalgia and sciatica without adequate evidence. The company remains barred from repeating those specific claims.
Is the Omron Avail PM601 still sold?
At retailers, yes. On Omron’s own current pages, no. Avail PM601 was a wireless, Bluetooth-connected, dual-channel TENS unit. The unit ran two electrode pads independently, which suits treating two areas at once. Retailers including Amazon, Best Buy and Walgreens still list it at $199.99. However, it is missing from omronhealthcare.com’s own current pain-management page. That page lists exactly two models: the Max Power Relief TENS Unit PM500 ($79.99, wired, single-channel) and the Pocket Pain Pro TENS Unit PM400. Both are simpler, cheaper devices than the wireless dual-channel Avail.
That is a real downgrade in what Omron itself promotes, not just a price cut. Omron’s site does not say plainly whether Avail can still be ordered direct or is being sold down as retailer stock. We could not confirm it either way.
Is iReliev a good wearable TENS pain relief system?
Yes, and it is the steadiest of the three. iReliev’s therapeutic wearable system runs $219.95 on ireliev.com, against a $249.95 list price (checked October 10, 2026). It is FDA-cleared per its own listings and confirmed as a registered device in the FDA’s Global Unique Device Identification Database. Unlike the other two, it combines TENS with EMS (electrical muscle stimulation) in one wireless, rechargeable, pod-based system. It comes in 2-pod or 4-pod configurations, depending on how many areas you want to treat. It is sold by the same company, the same way as the last time this was checked, though the price is now $20 higher. Because the other two brands just changed ownership or channel, that stability counts as value.
Replacement electrode pads run $29.95 for a wireless large-pad refill kit (regularly $39.95) directly from ireliev.com. That is the one clean, sourced consumable price across all three devices. Neither Quell’s nor Omron’s maker publishes a current replacement-pad price we could verify at the time of this update.
When is a wearable TENS pain relief device the wrong buy?
- Buying Quell 2.0 assuming NeuroMetrix still runs it independently. It does not. Confirm whether NeuroMetrix or electroCore fulfills your order and handles support before you buy.
- Confusing Quell 2.0 with Quell Fibromyalgia. They are different products under different regulatory pathways, and one requires a prescription.
- Assuming Omron Avail is Omron’s current TENS offering. It is not on the company’s current page. If wireless dual-channel operation matters to you, confirm with Omron whether Avail is still manufactured before ordering leftover retailer stock.
- Treating “FDA cleared” as validating every marketing claim layered on top of it. Quell’s history shows why. The clearance was real, and the company still paid $4 million over what it said beyond that clearance.
A search of CPSC.gov and Health Canada’s recall database for Quell, NeuroMetrix, Omron and iReliev turned up no product recalls for any of the three as of this update.
Which wearable TENS pain relief device should you skip?
Skip Quell 2.0 unless you have confirmed directly with the seller which company you are buying from and who handles support going forward. That means NeuroMetrix or electroCore. The device itself still works as designed. The business behind it is mid-transition.
Skip the Omron Avail if you want a device with a confirmed future. A model that has dropped off the maker’s own current page means betting on remaining stock rather than an actively supported product.
Skip iReliev only if you want TENS alone, with no EMS muscle-stimulation function bundled in. Its combined system is the one meaningful trade-off against the other two.
For most people, iReliev is the safer buy right now. It is the same company with the same product, a published replacement-pad cost and no ownership uncertainty. Omron’s name still carries weight if you can confirm Avail is genuinely still supported. Quell 2.0 is the one to research hardest before buying. The TENS technology did not change. The company selling it did.
Prices are approximate, current as of publication, and change frequently — confirm the latest price with the retailer before buying.
Looking at recovery from a different angle? See our recovery and readiness wearables comparison. Browse more in our Wearable Tech category.
